Literature DB >> 18071878

CD72 polymorphism associated with child-onset of idiopathic thrombocytopenic purpura in Chinese patients.

Jianhui Xu1, Shihong Lu, Jie Tao, Zeping Zhou, Zhenping Chen, Ying Huang, Renchi Yang.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) is a disease putatively relating to abnormal immune function and auto-antiplatelet immunoglobulin. We examined whether polymorphism of CD72, an inhibitory receptor of B cells, affect the susceptibility to ITP, or associated with the clinical characteristics of ITP. A case-control study was carried out in 206 Chinese ITP patients and 169 healthy controls. The detection of variable number of tandem repeats in CD72 intron 8 was performed by polymerase chain reaction and subsequent analysis with polyacrylamide gel electrophoresis. We did not find direct association between CD72 genotypes and susceptibility to ITP. The haplotype that contained one repeat of 13 nucleotides in intron 8 (designated as *1, and haplotype containing two repeat of 13 nucleotides in intron 8 is designated as *2) was significantly associated with early first onset age (< or = 14) in ITP patients (P = 0.03). ITP patients with CD72*1\*1 and *1\*2 genotype had a 3.09-fold [95% confidence interval (CI), 1.32-7.25] and 1.98-fold (95% CI, 0.92-4.25) increased risk of appearing ITP manifestation at their childhood respectively. The haplotype CD72*1 is apparently a risk allele, whereas CD72*2 a protective allele for child-onset of ITP disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18071878     DOI: 10.1007/s10875-007-9158-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  36 in total

1.  Refractory autoimmune thrombocytopenic purpura treatment with Rituximab.

Authors:  K Patel; J Berman; A Ferber; J Caro
Journal:  Am J Hematol       Date:  2001-05       Impact factor: 10.047

2.  CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation.

Authors:  C Pan; N Baumgarth; J R Parnes
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

Review 3.  Immune thrombocytopenic purpura.

Authors:  Douglas B Cines; Victor S Blanchette
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

4.  Activation of lyn, blk, and btk but not syk in CD72-stimulated B lymphocytes.

Authors:  C Venkataraman; N Muthusamy; S Muthukkumar; S Bondada
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

5.  Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children.

Authors:  B Gesundheit; G Cividalli; A Freeman; S Yatziv; G Koren; S Baruchel
Journal:  Eur J Haematol       Date:  2001-05       Impact factor: 2.997

Review 6.  Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update.

Authors:  R Yang; Z C Han
Journal:  Int J Hematol       Date:  2000-01       Impact factor: 2.490

7.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

8.  CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B.

Authors:  Yuki Hitomi; Naoyuki Tsuchiya; Aya Kawasaki; Jun Ohashi; Takeshi Suzuki; Chieko Kyogoku; Toru Fukazawa; Sasitorn Bejrachandra; Usanee Siriboonrit; Dasnayanee Chandanayingyong; Puan Suthipinittharm; Betty P Tsao; Hiroshi Hashimoto; Zen-ichiro Honda; Katsushi Tokunaga
Journal:  Hum Mol Genet       Date:  2004-09-30       Impact factor: 6.150

9.  The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Authors:  Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

10.  Major histocompatibility complex-restricted, polyclonal B cell responses resulting from helper T cell recognition of antiimmunoglobulin presented by small B lymphocytes.

Authors:  H P Tony; D C Parker
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Genetic studies in pediatric ITP: outlook, feasibility, and requirements.

Authors:  Anke K Bergmann; Rachael F Grace; Ellis J Neufeld
Journal:  Ann Hematol       Date:  2010-03-23       Impact factor: 3.673

2.  CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases : English version.

Authors:  T Tsubata
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

Review 3.  [CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases. German version].

Authors:  T Tsubata
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

4.  CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function.

Authors:  Hsin-Jung Wu; Subbarao Bondada
Journal:  J Clin Immunol       Date:  2008-12-06       Impact factor: 8.542

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.